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 Abstract 
 Background: The use of automated immunometric 
methods for the detection of anti-thyroid peroxidase anti-
bodies (TPOAb), the main serological marker of autoim-
mune thyroid diseases (AITD), has expanded in recent 
years. However, it is not known whether these new 
automated platforms have improved the diagnostic per-
formance of TPOAb assays. The aim of this study was to 
evaluate the potential improvement of the inter-method 
agreement of current automated third generation systems, 
12  years after a previous study, which had assessed the 
analytical variability between semi-automated second 
generation methods of TPOAb detection. 
 Methods: Eight pools of sera from patients with chronic 
lymphocytic thyroiditis, exhibiting different TPOAb con-
centrations, were collected from routine laboratory diag-
nostics and distributed to seven companies throughout 
Italy. All automated third generation methods were cali-
brated against the Medical Research Council (MRC) refer-
ence preparation 66/387. 
 Results: The overall mean variability (CV) was 93.6% 
when results were expressed in part as arbitrary Units 
(U/mL) and in part as International Units (IU/mL). The 
conversion of all values in IU/mL resulted in a significant 
decrease of CV (49.8%). The CV expressed as COM (cut-off 
concentration multiples) was 64.0%. Agreement of quali-
tative results was 95.3% with a pronounced difference in 
the threshold values proposed by manufacturers (range 
3.2 – 35.0 IU/mL). 
 Conclusions: These findings confirm the improvement of 
harmonisation between different methods of automated 
third generation TPOAb assays. Nevertheless, further 
efforts should be made in the definition of the positive 
cut-off concentration to avoid misclassification of AITD 
patients as well as in a new international reference prepa-
ration and in the autoantigen purification modality. 
 Keywords:  anti-thyroid peroxidase antibodies;  autoim-
mune thyroid disease;  automated platforms;  harmonisa-
tion;  immunoassay. 
 Introduction 
 Autoimmune thyroid diseases (AITD) are the most fre-
quent organ-specific autoimmune diseases in the world, 
affecting 5% – 10% of the population. The clinical picture 
of AITD consists of chronic lymphocytic thyroiditis [i.e., 
Hashimoto ’ s thyroiditis (HT)] and primary hyperthyroid-
ism [i.e., Graves ’ disease (GD)], in which the entire spec-
trum of thyroid function disorders is represented  [1] . 
 The diagnosis of AITD is based on the measurement 
of the circulating thyroid specific autoantibodies. This is 
undertaken in addition to clinical representation and func-
tional/imaging data, as is common practice for other auto-
immune diseases. Amongst the known types of thyroid 
autoantibodies, anti-thyroid peroxidase (TPOAb) and anti-
thyrotropin receptor (TRAb) antibodies are hallmarks for the 
diagnosis of AITD  [2, 3] , as confirmed by recent guidelines 
for the clinical management of thyroid diseases  [4 – 8] . 
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 TPOAb are the main serological marker of AITD, as 
they are detected in the sera of the majority of patients 
with GD ( > 80%), HT ( > 90%) and post-partum thyroiditis 
( > 70%). However, they are also detectable in 10% – 20% of 
healthy subjects  [2, 9] . In AITD patients ’ sera TPOAb are 
predominantly IgG of all subclasses, with high levels of 
concentration (up to mg/mL)  [10] . 
 In recent years, the methods for the measurement of 
circulating autoantibodies and in particular of TPOAb have 
markedly evolved encompassing three generations of ana-
lytical technologies  [11] . The use of sensitive automated 
third generation immunometric methods has progres-
sively expanded in clinical laboratories  [1, 12 – 14] . However, 
it is not known to what extent these new platforms have 
improved in terms of diagnostic accuracy with respect to 
the former methods. Due to the known problems of vari-
ability and low level of standardisation, several authors 
have underlined the need to assess the analytical perfor-
mance of commercially available TPOAb assays  [7, 12] . 
 Twelve years ago, the Study Group on Autoimmunol-
ogy of the Italian Society of Laboratory Medicine (SIMeL) 
demonstrated a high analytical variability between 
methods for the detection of TPOAb in a collaborative 
study with biomedical industries  [15] : at that time, 10 dif-
ferent semi-automated second generation methods were 
assessed. In order to evaluate potential improvement of 
the inter-methods agreement of current automated third 
generation systems, the study has been replicated with 
eight fully automated systems for TPOAb detection pro-
duced by seven participating companies. 
 Materials and methods 
 Eight pools of sera from patients with chronic lymphocytic thyroidi-
tis, exhibiting diff erent TPOAb concentrations, were collected within 
1 month from routine laboratory diagnostics, subdivided into ali-
quots of 0.5 mL and stored at  – 80  ° C. 
 Patients were diagnosed according to typical thyroid ultrasound 
pattern and thyroid-stimulating hormone (TSH) increase, above the 
upper reference limit of 4.0 mU/L. Enrolled subjects gave informed 
consent for participation in the study. 
 The aliquots were distributed to seven companies that produce 
analytical systems and reagents for TPOAb assay: Abbott Laborato-
ries (Chicago, IL, USA), Beckman-Coulter (Brea, CA, USA), DiaSorin 
(Saluggia, Italy), Roche Diagnostics (Mannheim, Germany), Sie-
mens Healthcare Diagnostics (Erlangen, Germany), Thermo Fisher 
Scientifi c B.R.A.H.M.S (Hennigsdorf, Germany), Tosoh Corporation 
(Tokyo, Japan). In total, eight third generation methods/kits (5 CLIA, 
1 ECLIA, 1 TRACE, 1 FEIA) were employed ( Table 1 ). Each participat-
ing company was invited to conduct the determination in two of their 
own laboratories and/or public hospital laboratories for a total of 16 
laboratories throughout Italy (see Supplemental Data, Table 1). All 
the immunometric methods were calibrated against the reference 
Medical Research Council (MRC) preparation 66/387 and imple-
mented in automated instruments. Native (3/8) or recombinant (5/8) 
antigens coated on the solid-phase were used for TPOAb assay. 
 Quantitative results were expressed in International Units (IU/
mL) and in multiples of the threshold value (cut-off  multiples: COM), 
calculated as the ratio between each analytical result and the pro-
posed cut-off  concentration (both expressed in IU/mL). In two of 
the eight methods/kits, results were initially expressed in arbitrary 
Units (U/mL) as suggested by the manufacturers and subsequently 
in IU/mL, obtained by introducing conversion factors. Concordance 
between results was calculated from the qualitative data (positive/
negative). 
 Data were reported as mean and range (min-max) for each 
method. The variability between the two laboratories using the same 
method (intra-method variability) and the total variability between 
methods (overall variability) were expressed in terms of coeffi  cient 
of variation (CV). Diff erences between absolute values and their 
corresponding COMs were determined by paired Student ’ s t-test. 
p-Value  < 0.05 was considered statistically signifi cant for all tests 
(GraphPad Prism Soft ware, version 4.0, San Diego, CA, USA). 
 Results 
 The overall variability of the quantitative results was 
93.6% (range 62.0% – 118.1%) ( Figure 1 ) (see Supplemen-
tal Data, Table 2). Two methods/labs (E and G) clearly 
 Table 1   Participating companies, instruments and methods used for TPOAb detection. 
Company   Instrument   Method/Tracer   Code
Abbott, USA   Architect (i1000-i2000)   CLIA/Acridinium esters/salts    A 
Beckman Coulter, USA   Unicel (Dxl 800-DxC 880i)   CLIA/Dioxetane phosphate    B 
DiaSorin, Italy   Liaison   CLIA/Isoluminol derivatives    C 
Roche Diagnostics, Germany   Cobas 8000-Modular E   ECLIA/Ruthenium bis-pyridyl    D 
Siemens HD, Germany   Centaur XP   CLIA/Acridinium esters    E 
Siemens HD, Germany   Immulite 2000 XPi   CLIA/Dioxetane phosphate    F 
Thermo Fisher BRAHMS, Germany  Kryptor-Kryptor Compact   TRACE/Europium cryptate    G 
Tosoh Corporation, Japan   AIA 2000   FEIA/4-methylumbelliferyl phosphate    H 
 CLIA, chemioluminescent immunoassay; ECLIA, electrochemiluminescent immunoassay; TRACE, time resolved amplified cryptate emission; 
FEIA, fluorimetric enzyme immunoassay. 
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 Figure 1   TPOAb results, expressed in IU/mL or U/mL in the eight pools before correction. 
 Columns represent the coefficient of variation and black circles the mean value with range. The overall mean CV of the quantitative results 
was 93.6% with a range of 62.0% – 118.1%. 
showed higher results than those of the other methods: a 
detailed analysis of the assay characteristics highlighted 
that the two methods/labs expressed the results in arbi-
trary Units (U/mL) instead of International Units (IU/mL). 
The correction of values in IU/mL, obtained by introduc-
ing a conversion factor (0.333 for the E method and 0.175 
for the G method), resulted in a significant reduction of 
variability, that was 49.8% (range 23.1% – 104.5%) ( Figure 
2 ), (see Supplemental Data, Table 3).  Figure 3 illustrates 
the same results expressed as COM: the overall mean CV 
was 64.0% (range 36.2% – 87.3%) (see Supplemental Data, 
Table 4). The difference between the two means was not 
significant (p = 0.4) ( Table 2 ). 
 The percentage agreement between qualitative 
results, subdivided according to sera and methods, is 
shown in  Figure 4 : overall concordance was 95.3% with 
three false negative results in pool 3 (see Supplemental 
Data, Table 5). Notably, there is a pronounced difference 
in the threshold values of positivity proposed by manufac-
turers, ranging from 3.2 IU/mL (H method) to 35.0 IU/mL 
(F method) (see Supplemental Data, Table 5). 
 The intra-method variability between each pair of 
laboratories is shown in  Figure 5 and ranges from 2.6% 
(A method) to 15.7% (G method). Of note, the variabil-
ity between methods tends to decrease with increasing 
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 Figure 2   TPOAb results, expressed in IU/mL in the eight pools after correction. 
 Columns represent the coefficient of variation and black circles represent mean value with range. The overall mean CV of the quantitative 
results was 49.8% with a range of 23.1% – 104.5%. 
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 Figure 3   TPOAb results, expressed as cut-off concentration multiples (COM) in the eight pools. 
 Columns represent the coefficient of variation and black circles the mean value with range. The overall mean CV of the quantitative results 
was 64.0% with a range of 36.2% – 87.3%. 
 Table 2   Comparison of overall mean variability calculated from 
results expressed in IU/mL and in COM. 
Antibody   Mean CV, %   Min-Max, %   p-Value 
TPOAb, IU/mL   49.8  23.1 – 104.5  n.s.
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 Figure 4   Agreement between qualitative results of TPOAb testing 
in the eight pools. 
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 Figure 5   Intra-method variability between laboratories. 
 Intra-method variability (CV) ranged from 2.6% to 15.7%. Data were 
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 Figure 6   Variability between methods in relation to TPOAb 
concentration. 
 Variability (CV) between methods tended to decrease with increas-
ing TPOAb concentration. Data were expressed as mean and range 
(min-max). 
 Discussion 
 About a decade ago, in the previous study, it was observed 
that  “ despite the improvement of current analytical pro-
cedures for TPOAb immunoassay derived by technology 
advancement, there was an unexpected and pronounced 
analytical variability in the quantitative results among 
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the various methods ”  [15] . In the present study, taking 
into account the technological evolution from second 
generation semi-automated to the recent third genera-
tion fully-automated platforms/systems for the TPOAb 
measurement, a significant improvement of the diagnos-
tic accuracy and the harmonisation of the results was to 
be expected. The present results show, however, that the 
level of standardisation is still quite low. This is likely 
due to four main factors: a) the analytical variables of the 
assays; b) the use of international reference preparations; 
c) the definition of the positive cut-off concentration; and 
finally d) the autoantigen purification procedures. 
 In the present study, considering the results calcu-
lated according to manufacturers ’ indication, the overall 
variability of the automated method for TPOAb meas-
urement is even higher than in the first study: 93.6% vs. 
76.0%  [15] . It is worth noting that the laboratories of two 
manufacturers use arbitrary units derived from secondary 
 ‘ in house ’ standards instead of the International Units of 
the reference MRC preparation 66/387. This source of vari-
ability (b factor, see above) significantly affects the agree-
ment of results between methods. In fact, by introducing 
appropriate correction factors, the analytical variability 
decreases from 93.6% to 49.8%. The combined ameliora-
tion of b factor and a factor, which largely depends upon 
the degree of automation  [15] , results in an improved 
harmonisation. 
 Regarding the c point (the definition of cut-off, as the 
upper reference limit) there is no doubt that this factor 
strongly affects the variability between methods. As a 
matter of fact, the variability increased from 62.9% in the 
earlier study to 67.0% of the present study. The cut-off 
values proposed by manufacturers do not always fulfil the 
international recommendations, which suggest the use of 
direct methods on a reference sample of 120 young male 
adults  [7] , nor are produced by means of indirect methods 
on current data from routine diagnostics stored in the 
laboratory databases, as proposed  [16] . These approaches 
could be adopted by every clinical laboratory, as a two-
step strategy  [16] : this might allow a harmonisation of the 
different proposed cut-offs, currently ranging from 3.2 to 
35.0  IU/mL with a 10-fold variation between minimum 
and maximum, as indicated also in previous studies  [15 –
 17] . Consequently, the concordance of qualitative results, 
slightly lower with respect of the earlier study (95.3% vs. 
96.6%), could increase by reducing misclassification of 
patients with AITD. 
 Taking into account that the contribution of the 
intra-method variability (from 2.6% to 15.7%) (see Sup-
plemental Data, Table 5) to overall variability is reduced 
with respect to the previous study, the residual variability 
of 30% between the different automated TPOAb assays 
could lie in the autoantigen purification and in the differ-
ent representation of immunodominant epitopes of TPO 
on the solid phase. It is now demonstrated that polyclonal 
TPOAb present in the sera of patients with AITD are het-
erogeneous and react with several B-cell conformational 
and linear epitopes on the surface of TPO. 
 TPO is a large membrane-associated glycoprotein, 
composed of a propeptide, a myeloperoxidase (MPO)-
like domain (142-738 amino acid residues), a complement 
control protein (CCP)-like domain (739-795 amino acid 
residues), an epidermal growth factor (EGF)-like domain 
(796-841 amino acid residues), a single transmembrane 
region and a short intracellular tail  [2, 18] . The MPO, CCP 
and EGF-like domains share a high sequence homology 
with MPO, CCP and EGF proteins, respectively. Two differ-
ent hinge regions are located between the MPO- and CCP-
like domains and CCP- and EGF-like domains  [2] . 
 Two overlapping domains, termed A (IDR-A) and B 
(IDR-B), constitute the immunodominant region (IDR) of 
TPO  [19] . However, the immunological response to other 
regions of TPO (non-A/non-B IDR) may occur in patients 
with AITD or non-autoimmune thyroid diseases: these 
epitopes are linear and formed by continuous amino acid 
sequences  [2, 9, 10, 20 – 24] . The distribution of IDR-A-, 
IDR-B, and non-IDR-A/IDR-B antibodies is approximately 
25%, 50% and 25%, respectively  [2, 20] . These regions are 
dependent upon the densely folded structure of TPO, with 
the MPO- and CCP-like domains lying in close proximity: 
the IDR forms a single complex on TPO, centred around 
residues 599-617 within the MPO-like domain, whereas 
the EGF-like domain, transmembrane region and propep-
tide may not be involved in antibody binding. However, 
the CCP- and EGF-like domains and their  ‘ hinge ’ region 
help maintain the three-dimensional structure of TPO 
required for antibody binding  [2, 9, 22, 24] . 
 TPO can be prepared in small amounts from human 
thyroid tissue, particularly hyperplastic thyroids. Using 
recombinant technology, TPO can be obtained in larger 
amounts from eukaryotic cells, such as Chinese hamster 
ovary cells. A eukaryotic cell is required because autoanti-
bodies predominantly recognise conformational epitopes. 
As TPO is a membrane-associated protein, its purifica-
tion requires detergent solubilisation and limited tryptic 
digestion of the thyroid microsomal fraction. Further 
purification can be obtained by affinity purification using 
monoclonal antibodies to human TPO. Commercial kits 
generally contain purified TPO prepared by processes 
which are trade secrets  [25] . 
 It is conceivable that the different coating prepara-
tions of autoantigen (natural or recombinant) on solid 
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phases affect the proper exposure of the immunodomi-
nant epitopes recognised by the polyclonal antibodies 
present in serum of AITD patients. This may result in a 
lack of recognition/identification of some of them by the 
different methods  [26, 27] . 
 The results of this study confirm in part the expected 
improvement of harmonisation between the different 
methods of automated third generation TPOAb assay, 
which over the past 10 years have become popular in clin-
ical laboratories, replacing the semi-automated methods 
of the second generation. Further efforts must be made in 
the definition of the threshold values of positivity to avoid 
misclassification of patients with AITD. 
 Acknowledgments:  The authors thank companies and 
laboratories that contributed to the study. 
 Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission. 
 Financial support: None declared. 
 Employment or leadership: None declared. 
 Honorarium: None declared. 
 Competing interests: The funding organisation(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication. 
 References 
 1.  Tozzoli R, Villalta D, Kodermaz G, Bagnasco M, Tonutti E, Bizzaro 
N. Autoantibody profiling of patients with autoimmune thyroid 
disease using a new multiplexed immunoassay method. Clin 
Chem Lab Med 2006;44:837 – 42. 
 2.  Czarnocka B, Cocks Eschler D, Godlewska M, Tomer Y. Thyroid 
autoantibodies: thyroid peroxidase and thyroglobulin antibod-
ies. In: Shoenfeld Y, Meroni PL, Gershwin ME, editors. Autoanti-
bodies, 3rd ed. Amsterdam: Elsevier, 2014:365 – 73. 
 3.  Tozzoli R, Bagnasco M, Villalta D. Thyrotropin receptor antibod-
ies. In: Shoenfeld Y, Meroni PL, Gershwin ME, editors. Autoanti-
bodies, 3rd ed. Amsterdam: Elsevier, 2014:375 – 83. 
 4.  Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman 
E, Negro R, et al. Guidelines of the American Thyroid Association 
for the diagnosis and management of thyroid disease during 
pregnancy and post-partum. Thyroid 2011;21:1081 – 125. 
 5.  Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, 
et al. Hyperthyroidism and other causes of thyrotoxicosis: manage-
ment guidelines of the American Thyroid Association and American 
Association of Clinical Endocrinologists. Thyroid 2011;21:593 – 647. 
 6.  Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanock 
JI, et al. Clinical practice guidelines for hypothyroidism in adults: 
cosponsored by the American Association of Clinical Endocri-
nologists and the American Thyroid Association. Endocr Pract 
2012;18:988 – 1028. 
 7.  Baloch Z, Carayon P, Comte-Devolx B, Demers LM, Feldt-Rasmus-
sen U, Henry JF, et al. Laboratory medicine practice guidelines. 
Laboratory support for the diagnosis and monitoring of thyroid 
disease. Thyroid 2003;13:3 – 126. 
 8.  Brenta G, Vaisman M, Sgarbi JA, Bergoglio LM, Carvalho de 
Andrada N, Pineda Bravo P, et al. Clinical practice guidelines for 
the management of hypothyroidism. Aeq Bras Endocrinol Metab 
2013;57:265 – 99. 
 9.  Czarnocka B. Thyroperoxidase, thyroglobulin, Na( + )/I( + ) 
symporter, pendrin in thyroid autoimmunity. Front Biosci 
2011;16:783 – 802. 
 10.  McLachlan SM, Rapoport B. Thyroid peroxidase as an autoanti-
gen. Thyroid 2007;17:939 – 48. 
 11.  Tozzoli R, Bonaguri C, Melegari A, Antico A, Bassetti D, Bizzaro 
N. Current state of diagnostic technologies in the autoimmunol-
ogy laboratory. Clin Chem Lab Med 2013;51:129 – 38. 
 12.  La ’ ulu SL, Slev PR, Roberts WL. Performance characteristics of 
5 automated thyroglobulin and thyroperoxidase autoantibody 
assays. Clin Chim Acta 2007;376:88 – 95. 
 13.  Gonzalez C, Garcia-Berrocal B, Talavan T, Casas ML, Navajo 
JA, Gonzalez-Buitrago JM. Clinical evaluation of a microsphere 
bead-based flow cytometry assay for the simultaneous deter-
mination of anti-thyroid peroxidase and anti-thyroglobulin 
antibodies. Clin Biochem 2005;38:966 – 72. 
 14.  Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Danko 
K, et al. Vitamin D and autoimmune thyroid diseases. Cell Mol 
Immunol 2011;8:243 – 7. 
 15.  Tozzoli R, Bizzaro N, Tonutti E, Pradella M, Manoni F, Villalta D, 
et al. Immunoassay of anti-thyroid autoantibodies: high analyti-
cal variability in second generation methods. Clin Chem Lab 
Med 2002;40:568 – 73. 
 16.  Tozzoli R, Giavarina D, Villalta D, Soffiati G, Bizzaro N. Defini-
tion of reference limits for autoantibodies to thyroid peroxidase 
and thyroglobulin in a large population of outpatients using an 
indirect method based on current data. Arch Pathol Lab Med 
2008;132:1924 – 8. 
 17.  Sinclair D. Analytical aspects of thyroid antibodies estimation. 
Autoimmunity 2008;41:46 – 54. 
 18.  Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G, 
et al. Thyroperoxidase, an auto-antigen with a mosaic structure 
made of nuclear and mitochondrial gene modules. EMBO J 
1987;6:4193 – 6. 
 19.  Ruf J, Toubert ME, Czarnocka B, Durand-Gorde JM, Ferrand M, 
Carayon P. Relationship between immunological structure and 
biochemical properties of human thyroid peroxidase. Endocri-
nology 1989;125:1211 – 8. 
 20.  Jastrzebska-Bohaterewicz E, Gardas A. Proportion of antibodies 
to the A and B immunodominant regions of thyroid peroxidase in 
Graves and Hashimoto disease. Autoimmunity 2004;37:211 – 6. 
 21.  Bresson D, Rebuffat SA, Banga JP, Gardas A, Peraldi-Roux S. New 
insights into the conformational dominant epitopes on thyroid 
peroxidase recognized by human autoantibodies. Endocrinol-
ogy 2005;146:2834 – 44. 
 22.  Dubska M, Banga JP, Plochocka D, Hoser G, Kemp EH, Sutton BJ, 
et al. Structural insights into autoreactive determinants in thyroid 
peroxidase composed of discontinuous and multiple key contact 
amino acid residues contributing to epitopes recognized by 
patients ’ autoantibodies. Endocrinology 2006;147:5995 – 6003. 
 23.  Nielsen CH, Brix TH, Gardas A, Banga JP, Hegedus L. Epitope 
recognition patterns of thyroid peroxidase autoantibodies in 
Brought to you by | Azienda Ospedaliera S. Maria degli Angeli Biblioteca Sanitaria
Authenticated
Download Date | 10/28/14 10:20 AM
D ’ Aurizio et al.: Analytical variability of anti-thyroid peroxidase antibodies      7
healthy individuals and patients with Hashimoto ’ s thyroiditis. 
Clin Endocrinol 2008;69:664 – 8. 
 24.  Godlewska M, Czarnocka B, Gora M. Localization of key 
amino-acid residues in the dominant conformational epitopes 
on thyroid peroxidase recognized by monoclonal antibodies. 
Autoimmunity 2012;45:476 – 84. 
 25.  Burek CI, Rose NR, Caturegli P. Thyroglobulin, thyroperoxi-
dase, and thyrotropin-receptor autoantibodies. In: Shoenfeld 
Y, Gershwin ME, Meroni PL, editors. Autoantibodies, 2nd ed. 
Amsterdam: Elsevier, 2007:403 – 14. 
 26.  Godlewska M, Gora M, Buckle AM, Porebski BT, Kemp EH, Sutton 
BJ, et al. A redundant role of human thyroid peroxidase propep-
tide for cellular, enzymatic and immunological activity. Thyroid 
2014;24:371 – 82. 
 27.  Liu M-M, Li Q, Zhao L-L, Gao Y, Huang Y-Y, Lu G-Z, et al. Glyco-
sylation of recombinant human thyroid peroxidase ectodomain 
of insect cell origin has little effect on recognition by serum 
thyroid peroxidase antibody. Chin Med J 2013;126:2907 – 11. 
 Supplemental Material: The online version of this article (DOI: 
10.1515/cclm-2014-0545) offers supplementary material, available 
to authorized users. 
Brought to you by | Azienda Ospedaliera S. Maria degli Angeli Biblioteca Sanitaria
Authenticated
Download Date | 10/28/14 10:20 AM
